羅格列酮对代谢综合征患者PCI术后的影响.docVIP

罗格列酮对代谢综合征患者冠状动脉介入治疗术后的影响 韩晓丽1 邵静波1 张彩霞2 【摘要】目的 观察罗格列酮对代谢综合征患者冠状动脉介入治疗（PCI）术后再狭窄率及代谢指标的影响。方法随机分成对照组(按常规治疗)和罗格列酮组(常规治疗+罗格列酮治疗), 在行PCI术前1d，罗格列酮组患者在原来用药的基础上予罗格列酮 8mg，po qd，以后以4mg·d-1治疗；对照组采用原来药物治疗，不加用罗格列酮。2组患者术后常规随访6mo。 结果罗格列酮组升高了HDL-C，降低了TG、CRP，有统计学意义（P＜0.05）；有降低PCI术后支架内再狭窄率趋势；未增加不良心血管事件发生率。结论罗格列酮能改善代谢综合征患者的血糖、血脂代谢指标,并可减轻炎症反应，有益于减少PCI术后支架内再狭窄。 【关键词】罗格列酮；代谢综合征；再狭窄 Effect of rosiglitazone on the patients with metabolic syndrome after coronary intervention influence Han Xiaoli 1 Shao Jing-bo 1 Zhang Cai-xia 2 Abstract:Objective Rosiglitazone on metabolic syndrome coronary intervention (PCI) restenosis rate and metabolic indexes. Method Randomly divided into control group (according to conventional treatment) and rosiglitazone group (conventional therapy + rosiglitazone), preoperative PCI line 1d, rosiglitazone patients on the basis of the original drug to rosiglitazone 8mg, po qd, later to 4mg·d-1 treatment; the control group, the original medication, without rosiglitazone. Two groups of patients received postoperative routine follow-up 6mo. Result Rosiglitazone group had increased HDL-C, lower TG, CRP, there was significant (P 0.05); have reduced in-stent restenosis after PCI rate trends; not increase the incidence of adverse cardiovascular events. Conclusion Rosiglitazone in patients with metabolic syndrome can improve blood glucose and lipid metabolism, and reduce the inflammatory response, also reduce in-stent restenosis after PCI. Key words rosiglitazone; metabolic syndrome; restenosis PCI术后再狭窄的发生率较高,合并有代谢综合征（metabolicsyndrome,MS）的患者尤甚，再狭窄严重阻碍了冠状动脉介入治疗的临床运用。我们尝试新一代的降糖药罗格列酮Rosiglitazone Maleate Tablets)应用于冠状动脉介入治疗术后的MS患者，效果满意。 1 资料与方法 1.1 研究对象 选择我院行PCI术（以支架植入的靶病变残余狭窄为0，TIMI Ⅲ级血流，无并发症为成功标准）的MS患者，均符合适合中国人群的代谢综合征诊断标准建议 (中华医学会糖尿病分会，2004年)。 1.2 方法 入选患者60例，男33例，女27例，平均年龄57.8±8.8岁。随机分成对照组(按常规治疗，男16例，女14例，共30例，年龄57.3±9.1岁)和罗格列酮组(常规治疗+罗格列酮治疗，，男17例，女13例，共30例，年龄55.2±11.3岁), 在行PCI术前1d，TZDs组患者在原来用药的基础上予罗格列酮 (天津葛兰素史克公司，每片4mg) 8mg，po qd，以后以4mg·d-1治疗；对照组采用原来药物治疗，不加用TZDs。2组患者术后常规随